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Abstract Histatin 5 is a low molecular weight salivary protein
which is known to exhibit inhibitory activity against several
proteinases, including the cysteine proteinases gingipains. The
purpose of this study was to characterize the effect of salivary
histatin on the proteolytic activity of the cysteine proteinase
clostripain derived from the pathogen Clostridium histolyticum.
Using a synthetic nitroanilide substrate, we studied in detail the
inhibition of clostripain by histatin 5 and compared the effect of
this peptide to that of leupeptin, a known competitive inhibitor of
clostripain. It was found that the concentration of histatin 5
required to inhibit 50% of clostripain activity was 23.6 þ 1.6 nM.
Kinetic analysis revealed that histatin 5 is a competitive inhibitor
of clostripain with an inhibition constant (Ki) of 10 nM. The Ki
for the inhibition of clostripain activity against nitroanilide
substrate by leupeptin was found to be 60 nM, significantly
higher than that of histatin 5. Thus, histatin 5 inhibits clostripain
more effectively than leupeptin and other cysteine protease
inhibitors studied here. No significant proteolysis of histatin 5
was observed when histatin 5 was incubated at physiologic
concentrations with clostripain. The potent inhibition of clos-
tripain by histatin 5 points towards the possibility that this
protein may prevent establishment of clostridial infections and
therefore may have significant potential for the treatment of
diseases associated with this enzyme. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Histatin 5 is a member of a family of low molecular weight
histidine-rich salivary proteins secreted by human parotid and
submandibular/sublingual glands. The major family members
are histatin 1, 3 and 5 which contain 38, 32 and 24 amino acid
residues, respectively, and their primary structures have been
determined [1]. Histatins are known to exhibit bactericidal
and fungicidal activities against several oral pathogens,
although this property of histatins may re£ect only one of a
number of functional roles that these proteins have in vivo [1^
5]. Other antibacterial functions have been attributed to his-
tatins based on its inhibitory e¡ect on bacterial proteinases
[6,7]. Histatin 5, the smallest protein among the protein family
inhibits trypsin-like and collagenase activities of Porphyro-
monas gingivalis [6,7] as well as a cysteine proteinase from
Clostridium histolyticum [6].
The anaerobic bacterium C. histolyticum produces toxins
and proteolytic enzymes which are important virulence factors
implicated in gas gangrene syndrome, a severe pathologic con-
dition [8]. In this condition, collagenases and cysteine protein-
ases produced in large quantities are associated with lethal,
necrotizing and muscle digesting activities leading to massive
tissue destruction [9]. The cysteine proteinase clostripain has
been isolated and characterized as an important proteolytic
enzyme from C. histolyticum. Structural studies have shown
that clostripain is composed of two polypeptide chains which
are non-covalently associated [10^12]. Like many other cys-
teine proteinases, clostripain requires calcium ions for stability
and activity [13]. The substrate speci¢city has been demon-
strated to be similar to that of trypsin, in which hydrolysis
is restricted to substrates containing arginine or lysine. How-
ever, proteolysis by clostripain occurs in preference at the
carboxyl terminal side of arginine residues [14].
Although preliminary studies have shown that histatin 5
inhibits clostripain, very little is known about the kinetic
mechanism of this inhibition [6]. Therefore, the aim of the
present study was to further characterize the inhibition of
clostripain by salivary histatin 5 by determining the e¡ect of
this protein on the kinetic parameters KM and kcat, and to
compare its activity with leupeptin. We found that histatin 5
was more e¡ective than leupeptin, the strongest inhibitor of
clostripain previously reported.
2. Materials and methods
The materials used in this study were purchased from commercial
sources as follows: synthetic histatin 5 (DSHAKRHHGYKRKF-
HEKHHSHRGY, MW 3037) was purchased from American Peptide
Company (Sunnyvale, CA, USA). The preparation was subjected to
reverse phase high performance liquid chromatography (HPLC) anal-
ysis using an acetonitrile gradient to verify purity [1]. Clostripain,
benzamidine, iodoacetic acid, phenylmethylsulfonyl £uoride (PMSF),
N-tosyl-Lys-chloromethylketone (TLCK), E-64 (trans-epoxysuccinyl-
L-leucylamido-(4-guanidino)butane)), leupeptin, N-benzoyl-DL-argi-
nine p-nitroanilide (BAPNA), 3-(N-morpholino)propane-sulfonic
acid (MOPS), N-tris(hydroxymethyl)methyl-2-aminoethane sulfonic
acid (TES) and N,N-dimethylformamide were obtained from Sigma
(St. Louis, MO, USA). CaCl2W2H2O and dithiothreitol (DTT) were
purchased from Fisher (Pittsburgh, PA, USA).
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Clostripain activity was assayed spectrophotometrically. Clostripain
was activated in 10 mM MOPS, pH 7.4, containing 1 mM CaCl2 and
2.5 mM DTT for 3 h at 25‡C. After activation, clostripain (46 nM)
was added to 600 Wl of enzyme bu¡er (50 mM TES pH 7.4) contain-
ing the substrate BAPNA (80 WM) in the presence and absence of
histatin 5 (0.012^0.35 WM). The reaction was carried out in cuvettes of
1 cm light-path at 25‡C and the formation of product (p-nitroaniline)
was monitored by the increase in absorbance at 410 nm using a
Milton Roy Spectronic 1201 Spectrometer (Londonderry, NH,
USA). The velocity of the reaction was obtained from the initial slope
of plots of absorbance versus time. All data were corrected for the
absorbance of the enzyme^substrate mixture recorded immediately
upon mixing at time zero.
The KM and kcat were determined at 25‡C using BAPNA at con-
centrations ranging from 40 to 160 WM with ¢nal concentrations of 46
nM clostripain either in the absence or in the presence of two di¡erent
concentrations of histatin 5. Initial rates of hydrolysis were calculated
at ¢ve di¡erent concentrations of substrate and the type of inhibition
and Michaelis^Menten parameters were determined from Linewea-
ver^Burk plots [15] by using the equations derived from the linear
regression analysis of each curve. The kcat value was calculated apply-
ing the following equation: kcat = Vmax/[E] where [E] is the enzyme
concentration in the assay [16].
The inhibition constant (Ki) was estimated either by using the equa-
tion applicable to reversible, competitive type inhibitors, Ki = IC50/
(1+S/KM) [17,18] or extrapolated from a Dixon plot [15]. Three di¡er-
ent concentrations of BAPNA (60, 80 and 106 WM) were used in the
absence or in the presence of increasing concentrations of histatin 5 to
determine the Ki from a Dixon plot.
To analyze whether histatin 5 is susceptible to proteolytic degrada-
tion under the conditions used for the inhibition assays, activated
clostripain was incubated at room temperature with histatin 5 in the
absence of BAPNA for di¡erent periods of time. The reaction mixture
consisted of 46 nM clostripain and 10 WM histatin 5 dissolved in TES
bu¡er pH 7.4 at a ¢nal volume of 800 Wl. Aliquots of 150 Wl were
collected at di¡erent time points and mixed with 40 Wl of acetic acid to
terminate the reactions. Subsequently, samples were ¢ltered through
0.45 Wm ¢lters (Millipore, Bedford, MA, USA) and subjected to re-
verse phase HPLC. Sample application to a TSK-GEL 5 Wm ODS-
120T column (4.6U250 mm) equipped with an Ultrasphere 5 Wm ODS
guard column was carried out in 0.1% tri£uoroacetic acid in water
(eluent A) and separations were performed with a linear gradient of
0.09% tri£uoroacetic acid to 30% acetonitrile/water (eluent B) over 40
min at a £ow rate of 1 ml/min. The protein elution pro¢le was moni-
tored at 230 nm.
3. Results and discussion
Inhibition of clostripain by histatin 5 was investigated using
the synthetic substrate BAPNA. A typical inhibition curve
was obtained when the activity of clostripain was measured
in the presence of histatin 5 (Fig. 1). The IC50 value for this
inhibition was found to be 23.6 þ 1.6 nM (n = 3).
To compare the e¡ect of histatin 5 with other known pro-
teinase inhibitors, the activity of clostripain was measured in
the presence of 35 WM concentrations of inhibitors of cysteine
proteinases (iodoacetic acid, E-64 and leupeptin), of trypsin-
like proteinases (benzamidine and TLCK) and of a serine
proteinase (PMSF). Histatin 5, TLCK and leupeptin com-
pletely abolished clostripain activity while iodoacetic acid, a
known inhibitor of other cysteine proteinases [19], had limited
inhibitory activity against clostripain at the concentration
used (Table 1). As expected, the well established serine pro-
teinase inhibitor PMSF failed to inhibit clostripain. These
results demonstrate that histatin 5 is a potent inhibitor of
clostripain.
In order to study the kinetics of clostripain inhibition by
histatin 5 and determine the properties of this inhibition, en-
zyme activity was measured with clostripain in the absence,
and in the presence of 12 and 24 nM histatin 5. These con-
centrations of histatin 5 were chosen from the plot of activity
versus inhibitor concentration (Fig. 1). The initial velocity
(AU/min) of the reaction was obtained for each concentration
of substrate used and the data were presented in a Linewea-
ver^Burk plot.
As shown in Fig. 2A the reciprocal plots of the control and
in the presence of inhibitor intercept at a common point on
the y-axis indicating that the Vmax is unchanged in the pres-
ence of histatin 5. Furthermore, the KM values determined
from the intercepts at the x-axis demonstrate that the KM
values increase when the histatin 5 concentration increases
(Fig. 2A). These kinetic features are characteristic of compet-
itive enzyme inhibition. Means and standard deviations of the
kinetic parameters from three separate experiments are given
in Table 2. Analysis of Vmax and kcat values obtained for
clostripain revealed that these values were not altered in the
presence of histatin 5. Increases were observed in the KM and
decreases in the kcat/KM values, consistent with the competi-
tive inhibition.
Kinetic experiments were also carried out with the positive
control, leupeptin, which veri¢ed that this peptide is a com-
petitive inhibitor of clostripain (Fig. 2B) [13].
Fig. 1. E¡ect of histatin 5 on clostripain activity. Histatin 5 was
added to the enzyme^substrate mixture and the velocity of cleavage
of BAPNA was recorded spectrophotometrically as an increase in
absorbance at 410 nm. Activity is expressed as a percent of control
solutions containing enzyme without inhibitor. The error bars indi-
cate the standard deviations for three experiments.
Table 1
E¡ect of inhibitors on the activity of clostripaina










aInhibitors were added to the enzyme^substrate mixture at a ¢nal
concentration of 35 WM and the activity was measured spectropho-
tometrically as an increase at 410 nm.
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The inhibition constant, Ki, for histatin 5 against clostripain
was determined. For this purpose, enzyme assays were per-
formed at three di¡erent concentrations of substrate (60, 80
and 106 WM) in the presence and absence of histatin 5. The Ki
was obtained graphically using a Dixon plot for competitive
inhibition. In this plot, 1/v (velocity) is plotted against inhib-
itor concentration at varying concentrations of substrate and
a series of straight lines was obtained converging to the point
that represents Ki =3[I]. The Ki value for the inhibition of
clostripain by histatin 5 was 10 nM. Furthermore, when the
Ki was calculated using the equation (Ki = IC50/(1+S/KM)) ap-
plicable for competitive inhibition, similar values were ob-
tained. The Ki (60 nM) for the inhibition of clostripain by
leupeptin was determined in a similar manner (data not
shown).
Since the competitive nature of the inhibition of clostripain
by histatin 5 indicates its interaction with the active site, it is
important to assess whether this inhibitor might be a potential
substrate for the enzyme, particularly in view of the fact that
histatin 5 contains arginine and lysine residues which could be
sites of cleavage by clostripain. When histatin 5 was incubated
at a physiologic concentration (10 WM) with 46 nM clostri-
pain, the same enzyme concentration used in the inhibition
assays, no signi¢cant turnover could be observed, even after
30 min of incubation. The concentrations of clostripain and
histatin 5 used in the initial rate assays were 46 and 24 nM,
respectively. Under these standard assay conditions, peptides
that might be formed due to possible histatin 5 proteolysis by
clostripain were not detectable in HPLC analyses. Even at
concentrations of clostripain and histatin 5 of 0.92 and 0.48
WM, respectively, the reaction mixture showed no evidence for
histatin 5 degradation by clostripain. Thus, it appears that the
inhibitory e¡ect of histatin 5 on clostripain activity against
BAPNA is not due to histatin 5 acting as a competing sub-
strate under the described conditions.
In summary, this study provides new information about the
kinetics of the inhibition of clostripain by histatin 5. Our
results clearly show that histatin 5 has a high inhibitory ac-
tivity toward clostripain as re£ected in the Ki value found for
this inhibition. To our knowledge, this is the most potent
inhibitor of clostripain ever reported in the literature. Earlier
studies have indicated leupeptin to be the most potent inhib-
itor of clostripain [13] but the present study found that hista-
tin 5 has a six-fold lower Ki than that of leupeptin. Therefore,
it is highly possible that under physiologic conditions histatin
acts as a natural inhibitor of this enzyme. Taken together,
these results point toward a novel property of histatin 5 be-
sides its well-known anticandidal activity. Furthermore, since
histatin 5 is a salivary peptide and therefore naturally exposed
to epithelial surfaces it is proposed that this protein could be
used for the prevention or treatment of topical infections such
as those caused by C. histolyticum.
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Fig. 2. Lineweaver^Burk plots of the inhibition of clostripain by
histatin 5 (A) and by leupeptin (B). Enzyme assays were carried out
with clostripain alone (8, 7) and in the presence of either histatin
5 at 12 nM (F) and 24 nM (R) or leupeptin at 100 nM (E) and
200 nM (O). Equations were obtained from linear regression analy-
sis of each line and were used to calculate the kinetic parameters
given in Table 2. Dashed lines are extensions of linear regression
lines and indicate that the inhibition of clostripain by histatin 5 and
leupeptin is competitive. Individual graphs represent the results of
triplicate experiments.
Table 2
Kinetic parameters of clostripain in the presence of histatin 5a
Vmax (AU/min) KM (WM) kcat (s31) kcat/KM (s31 M31U1036)
Clostripain only 0.25 þ 0.02 133 þ 9.0 5.4 þ 0.4 0.04 þ 0.001
Histatin 5 (12 nM) 0.23 þ 0.005 184 þ 14.5 5.0 þ 0.2 0.027 þ 0.002
Histatin 5 (24 nM) 0.24 þ 0.02 314 þ 7.2 5.2 þ 0.4 0.017 þ 0.001
aParameters were calculated using the equations obtained from the Lineweaver^Burk plots. Standard deviations given are for three separate ex-
periments.
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